Home  Media Press releases
|
|
|
| 4 June 2007 | 2007-06-04T00:00:00.0000000+01:00 |
| AstraZeneca Acquires Biologics Manufacturing Facility in Canada
AstraZeneca today announced that it has acquired a biologics manufacturing facility in Montreal, Canada, from DSM Biologics Inc. The facility, occupying 66,000 sq. ft, will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group. | Dr. John Patterson, AstraZeneca’s Executive Director, Development, said: “This is a further step in our global plan to accelerate the delivery of promising pre-clinical biopharmaceutical candidate drugs into our development portfolio. It extends the set of supply capabilities we have assembled through MedImmune and Cambridge Antibody Technology (CAT) and takes advantage of the biotechnology skills in Quebec.”
”This acquisition demonstrates our continued commitment to the province of Quebec,” said Mark Jones, President & CEO, AstraZeneca Canada Inc. “Ultimately, this investment will help strengthen our pipeline by building a larger portfolio of biological drugs so that we can deliver valued medicines to patients.”
Work will now start to re-commission the facility, and the company plans to commence full scale production in 2009.
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Karl Hard, Tel: +44 (0) 207 304 5322
Jörgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065
AstraZeneca:
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
Cambridge Antibody Technology (CAT):
Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients’ lives.
CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company’s strategy to develop a portfolio of antibody-based drugs.
CAT is part of the AstraZeneca group of companies.
CAT employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA.
For more information: www.cambridgeantibody.com |
|
|